Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S.
Drexel H, et al. Among authors: kaski jc.
Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):302-310. doi: 10.1093/ehjcvp/pvab048.
Eur Heart J Cardiovasc Pharmacother. 2022.
PMID: 34180504
Review.
No abstract available.